Adlai Nortye (NASDAQ:ANL – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.07, FiscalAI reports. The company had revenue of $6.53 million for the quarter, compared to analysts’ expectations of $4.72 million.
Adlai Nortye Stock Up 3.0%
NASDAQ ANL traded up $0.39 on Friday, reaching $13.25. The company had a trading volume of 56,281 shares, compared to its average volume of 409,984. Adlai Nortye has a 1 year low of $0.88 and a 1 year high of $17.25. The firm has a 50-day moving average of $11.37 and a 200-day moving average of $10.75.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. Oppenheimer assumed coverage on Adlai Nortye in a research report on Thursday, May 28th. They set an “outperform” rating and a $32.00 price target for the company. JonesTrading initiated coverage on Adlai Nortye in a research note on Thursday, May 14th. They issued a “buy” rating and a $22.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Adlai Nortye in a report on Monday, June 22nd. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Finally, HC Wainwright lifted their price target on shares of Adlai Nortye from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Adlai Nortye currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.
About Adlai Nortye
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Recommended Stories
- Five stocks we like better than Adlai Nortye
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
